Illumina announces strategy to accelerate value creation
Illumina (NASDAQ: ILMN) has announced a new strategy to accelerate value creation, aiming to boost revenue growth to high single digits over the next three years. The company plans to achieve this through innovations in its core genomics portfolio, enabling transformative applications using multiomics and offering higher quality insights to customers. Illumina expects to deliver double-digit to teens non-GAAP diluted earnings per share growth from 2025-2027.
The company is also partnering with the Broad Institute of MIT and Harvard to advance single-cell sequencing, leveraging Illumina's Fluent technology. Key focus areas include reinventing the genome, unlocking deeper biology, simplifying NGS operations, and turning data into insights. Illumina aims to accelerate revenue growth while improving profitability through operational efficiencies and strategic cash flow allocation.
Illumina (NASDAQ: ILMN) ha annunciato una nuova strategia per accelerare la creazione di valore, puntando ad aumentare la crescita dei ricavi a cifre alte a una sola cifra nei prossimi tre anni. L'azienda prevede di raggiungere questo obiettivo attraverso innovazioni nel suo portafoglio genomico principale, abilitando applicazioni trasformative usando la multiomica e offrendo intuizioni di alta qualità ai clienti. Illumina si aspetta di realizzare una crescita a doppia cifra fino ai teen per quanto riguarda l'utile per azione diluito non-GAAP dal 2025 al 2027.
La società sta anche collaborando con il Broad Institute del MIT e di Harvard per far avanzare il sequenziamento a singola cellula, sfruttando la tecnologia Fluent di Illumina. Le aree di focus principali includono reinventare il genoma, sbloccare una biologia più profonda, semplificare le operazioni NGS e trasformare i dati in intuizioni. Illumina mira ad accelerare la crescita dei ricavi migliorando al contempo la redditività attraverso efficienze operative e un'allocazione strategica del flusso di cassa.
Illumina (NASDAQ: ILMN) ha anunciado una nueva estrategia para acelerar la creación de valor, con el objetivo de aumentar el crecimiento de los ingresos a cifras altas de un solo dígito en los próximos tres años. La empresa planea lograr esto a través de innovaciones en su cartera de genómica principal, permitiendo aplicaciones transformadoras utilizando multiómicas y ofreciendo información de mayor calidad a los clientes. Illumina espera conseguir un crecimiento de ganancias por acción diluido no-GAAP de cifras dobles a adolescentes desde 2025 hasta 2027.
La compañía también está colaborando con el Broad Institute del MIT y Harvard para avanzar en la secuenciación de células individuales, aprovechando la tecnología Fluent de Illumina. Las áreas clave de enfoque incluyen reinventar el genoma, desbloquear una biología más profunda, simplificar las operaciones de NGS y convertir datos en ideas. Illumina tiene como objetivo acelerar el crecimiento de los ingresos mientras mejora la rentabilidad a través de eficiencias operativas y una asignación estratégica del flujo de caja.
일루미나(NASDAQ: ILMN)는 가치 창출을 가속화하고 향후 3년 동안 수익 성장을 높은 한 자릿수 이상으로 높이는 것을 목표로 하는 새로운 전략을 발표했습니다. 회사는 핵심 유전체 포트폴리오에서의 혁신을 통해 다중 오믹스를 활용한 변혁적 응용 프로그램을 가능하게 하고 고객에게 더 높은 품질의 통찰력을 제공함으로써 이를 달성할 계획입니다. 일루미나는 2025년부터 2027년까지 비GAAP 희석 주당 순이익이 두 자릿수에서 중학생 수준으로 성장할 것으로 예상하고 있습니다.
회사는 또한 MIT와 하버드의 브로드 연구소와 협력하여 일인 세포 서열 결정 연구를 진행하며, 일루미나의 플루언트 기술을 활용하고 있습니다. 주요 초점 영역에는 유전체 재창조, 심층 생물학 잠금 해제, NGS 운영 간소화, 데이터 통찰력으로의 전환이 포함됩니다. 일루미나는 운영 효율성과 전략적 현금 흐름 할당을 통한 수익 성장 가속화와 함께 수익성 향상을 목표로 하고 있습니다.
Illumina (NASDAQ: ILMN) a annoncé une nouvelle stratégie pour accélérer la création de valeur, visant à accroître la croissance des revenus à des chiffres élevés à un seul chiffre au cours des trois prochaines années. La société prévoit d'atteindre cet objectif grâce à des innovations dans son portefeuille génomique principal, permettant des applications transformatrices utilisant des multi-omiques et offrant des aperçus de haute qualité aux clients. Illumina s'attend à réaliser une croissance à deux chiffres jusqu'à l'adolescence du bénéfice net par action dilué non-GAAP entre 2025 et 2027.
La société s'associe également avec le Broad Institute du MIT et d'Harvard pour faire avancer le séquençage à cellule unique, tirant parti de la technologie Fluent d'Illumina. Les domaines d'accent clés comprennent la réinvention du génome, le déverrouillage de biologie plus profonde, la simplification des opérations NGS et la transformation des données en aperçus. Illumina vise à accélérer la croissance des revenus tout en améliorant la rentabilité grâce à des gains d'efficacité opérationnelle et une allocation stratégique des flux de trésorerie.
Illumina (NASDAQ: ILMN) hat eine neue Strategie angekündigt, um die Wertschöpfung zu beschleunigen, mit dem Ziel, das Umsatzwachstum in den nächsten drei Jahren auf hohe einstellige Ziffern zu steigern. Das Unternehmen plant, dies durch Innovationen in seinem zentralen Genomikportfolio zu erreichen, die transformative Anwendungen durch Multiomics ermöglichen und den Kunden qualitativ hochwertige Einblicke bieten. Illumina erwartet, von 2025 bis 2027 ein Wachstum des verwässerten Gewinns pro Aktie ohne GAAP im zweistelligen Bereich bis hin zu Teenagerzahlen zu erzielen.
Das Unternehmen arbeitet auch mit dem Broad Institute des MIT und Harvard zusammen, um die Einzelzellsequenzierung voranzutreiben und dabei die Fluent-Technologie von Illumina zu nutzen. Zu den wichtigsten Fokusbereichen gehören die Neugestaltung des Genoms, das Entsperren tieferer Biologie, die Vereinfachung von NGS-Operationen und die Umwandlung von Daten in Erkenntnisse. Illumina strebt an, das Umsatzwachstum zu beschleunigen und gleichzeitig die Rentabilität durch betriebliche Effizienz und strategische Cashflow-Zuweisung zu verbessern.
- Projected revenue growth acceleration to high single digits by 2027
- Expected double-digit to teens non-GAAP diluted EPS growth from 2025 to 2027
- New research partnership with Broad Institute to advance single-cell sequencing
- Focus on innovations to enable transformative applications using multiomics
- Strategy to improve operational efficiencies and profitability
- Current challenging macroeconomic environment affecting customer relationships
Illumina's strategy update signals a positive trajectory for the company. The projected acceleration to high single-digit revenue growth by 2027 and double-digit to teens non-GAAP EPS growth from 2025-2027 are encouraging indicators. These targets, coupled with operational efficiencies and disciplined cash flow allocation, suggest improved financial performance ahead.
The focus on expanding whole-genome sequencing and developing multiomic workflows aligns with growing market demands. The partnership with the Broad Institute for single-cell sequencing advancements could open new revenue streams. However, investors should monitor execution risks and potential market challenges that could impact these ambitious growth targets.
Illumina's strategy to reinvent the genome and unlock deeper biology through multiomics is scientifically promising. The collaboration with the Broad Institute to advance single-cell sequencing, particularly the development of kits for large-scale PerturbSeq CRISPR screening, is a significant step forward. This could enable billion-cell experiments, potentially revolutionizing biomedical research.
The focus on integrating software/AI for data analysis and deciphering variants of unknown significance addresses a critical need in the field. If successful, these innovations could solidify Illumina's position as a leader in genomics technology and open new markets in personalized medicine and drug discovery.
Illumina's strategy aligns well with current market trends in genomics and precision medicine. The emphasis on making NGS easier to operate in laboratories and providing sample-to-insight workflow solutions addresses key pain points for researchers and clinicians. This could potentially expand Illumina's customer base and market share.
The company's focus on developing a software/AI platform for large data cohort analysis taps into the growing demand for bioinformatics solutions. However, competition in this space is intensifying and Illumina will need to demonstrate clear differentiation. The success of this strategy will largely depend on Illumina's ability to execute effectively and adapt to rapidly evolving customer needs in a competitive landscape.
-- Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio
-- Innovations to enable development of transformative applications using multiomics
-- Illumina to offer higher quality insights to customers, helping them improve the overall end-to-end workflow experience and lower cost
-- Delivering double digit to teens non-GAAP diluted earnings per share growth 2025-2027
-- Illumina and the Broad Institute of MIT and Harvard announce new research partnership to advance single-cell sequencing
"Illumina built the foundation of the genomics industry, and we will continue leading innovation across total sequencing workflows to support the next phase of our customers' success," said Jacob Thaysen, Chief Executive Officer of Illumina. "Over the next three years, we will bring to market impressive new innovations that will redefine the genome and drive significant, deeper biological insights through multiomics."
Today, Illumina and the Broad Institute of MIT and Harvard are also announcing a new research partnership to advance single-cell sequencing and accelerate adoption of high-capacity single-cell experiments, leveraging Illumina's Fluent technology. As part of their work together, Illumina and the Broad will partner on the development and validation of new kits to catalyze large-scale PeturbSeq CRISPR screening.
"Expanding our research partnership with Illumina to include Fluent's technology will support the Broad's efforts toward enabling billion cell experiments," said Niall Lennon, Senior Director of the Broad Institute's Genomics Platform. "Single-cell sequencing has transformed biomedical research in ways that were unimaginable as recently as 15 years ago. Right now it is one of the most exciting areas in biology."
Illumina is building new, scalable growth businesses that complement and accelerate its high-intensity, high-throughput sequencing franchise. The Company is executing on a series of innovations aligned with the diverse and evolving needs of its customers. These innovations will help them to:
- Reinvent the genome: Lead broader whole-genome sequencing (WGS) utility by revolutionizing the workflow with novel sample preparation and integrated software.
- Unlock deeper biology: Enable deeper biological insight with complete multiomic workflows that integrate with one another through interpretation and visualization tools.
- Make next-generation sequencing (NGS) easy to operate in the laboratory by providing sample-to-insight workflow solutions, including the best-in-class software and informatics capabilities to pave the way to deep and comprehensive answers.
- Turn data into insights: Deliver a software / AI platform that integrates and analyzes large data cohorts and deciphers variants of unknown significance.
Illumina expects its strategy to enable the company to accelerate its revenue growth to high single digits by 2027. The Company aims to drive double digit to teens non-GAAP diluted earnings per share (EPS) growth from 2025 to 2027 by accelerating revenue growth, leveraging operational efficiencies, and allocating its significant free cash flow using a systematic and disciplined approach.
"We have the right strategy to return to growth and increase our profitability. We are already executing that strategy and strengthening Illumina's relationship with customers in a challenging macroeconomic environment," said Ankur Dhingra, Chief Financial Officer of Illumina. "Looking ahead, we expect to see accelerating revenue growth over the next three years while also delivering differentiated earnings expansion."
Webcast details
The virtual event will begin at 8:00am Pacific Time. The event will feature presentations by members of Illumina's executive team and conclude with a Q&A session.
The webcast can be accessed through the Events & Presentations section of Illumina's Investor Relations website at investor.illumina.com. We recommend that participants pre-register for the event on our website or by using the following link: Illumina 2024 Strategy Update Registration. A replay will be posted on Illumina's Investor Relations website after the event and will be available for at least 30 days following.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) our ability to meet our revenue growth and earnings per share targets; (ii) changes in the rate of growth in the markets we serve; (iii) the volume, timing and mix of customer orders among our products and services; (iv) our ability to adjust our operating expenses to align with our revenue expectations; (v) our ability to manufacture robust instrumentation and consumables; (vi) the success of products and services competitive with our own; (vii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (viii) the impact of recently launched or pre-announced products and services on existing products and services; (ix) our ability to realize the anticipated benefits from prior or future actions to streamline and improve our R&D processes, reduce our operating expenses and maximize our revenue growth; (x) to deploy new products, services, and applications, and to expand the markets for our technology platforms; (xi) our ability to obtain approval by third-party payors to reimburse patients for our products; (xii) our ability to obtain regulatory clearance for our products from government agencies; (xiii) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xiv) uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth or armed conflict; (xv) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments and (xvi) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
The company provides forward-looking guidance on a non-GAAP basis. The company is unable to provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures because it is unable to predict with reasonable certainty the financial impact of items such as acquisition-related expenses, gains and losses from our strategic investments, fair value adjustments related to contingent consideration and contingent value rights, potential future asset impairments, restructuring activities, and the ultimate outcome of pending litigation without unreasonable effort. These items are uncertain, inherently difficult to predict, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, the company is unable to address the significance of the unavailable information, which could be material to future results.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Bonny Fowler
740-641-5579
PR@illumina.com
View original content:https://www.prnewswire.com/news-releases/illumina-announces-strategy-to-accelerate-value-creation-302221115.html
SOURCE Illumina, Inc.
FAQ
What is Illumina's revenue growth target for the next three years?
What is Illumina's earnings per share growth projection for 2025-2027?
What new partnership has Illumina announced for single-cell sequencing?
What are the key focus areas of Illumina's new strategy?
